Skip to Content

Mirati Therapeutics, Inc.

Merger

  • Date:
  • 10/10/2023
  • Company Name:
  • Mirati Therapeutics, Inc.
  • Stock Symbol:
  • MRTX
  • Company Name - Buyer:
  • Bristol Myers Squibb
  • Stock Symbol - Buyer:
  • BMY
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/10/2023

Case Finder

Locate any case using the tools below.

NEW YORK, October 10, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Mirati Therapeutics, Inc. (NASDAQ: MRTX) (“Mirati”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Bristol Myers Squibb (NYSE: BMY) (“Bristol Myers Squibb”).

On October 10, 2023, Mirati announced that it had entered into an agreement to be acquired by Bristol Myers Squibb in a $5.8 billion cash and CVR deal. Pursuant to the merger agreement, Bristol Myers Squibb will acquire all outstanding shares of Mirati for $58.00 per share in cash, representing a 52% premium to the 30-day VWAP as of the unaffected October 4, 2023 close. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, which will entitle its holder to receive a one-time potential payment of $12.00 in cash. The deal is expected to close by the first half of 2024.

Bragar Eagel & Squire is concerned that Mirati's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Mirati's stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Mirati Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: